Pharma News

Novo Nordisk has received a significant legal victory in China’s Supreme People’s Court, which affirmed the validity of the company’s semaglutide compound patent, strengthening intellectual property protections for one of its most important medicines.

Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for AXS-05 seeking approval for the treatment of agitation associated with Alzheimer’s disease, and has granted Priority Review designation to the filing. The regulatory body has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026, underlining the importance of this potential new therapy in an area of high unmet need.

A new peer-reviewed study has revealed that Sanghuangporus quercicola, a medicinal fungus long used in traditional practices across Asia, produces significantly varied secondary metabolites under different cultivation conditions, with notable in vitro antidiabetic activity emerging from the analyses.

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 37 new drug formulations under the Drugs (Prices Control) Order (DPCO), 2013, through an order issued on December 24, 2025. The decision, published in the Gazette of India, aims to regulate the prices of commonly used medicines across therapeutic segments, while ensuring affordability and transparency for consumers.

Johnson & Johnson has officially completed its acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company known for its innovative cancer-targeting technology, in a deal valued at USD 3.05 billion in cash.